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The envelope glycoprotein (Env) of human immunodeficiency virus is key to viral entry of
susceptible target cells and is therefore a major target for the design of vaccines and antiviral
drugs. C-C chemokine receptor type 5 (CCR5)-using (R5) Env is the predominant phenotype
associated with early transmission and acute infection. This study investigated the mechanism of
CCR5 use and the sensitivity to CCR5 inhibitors of a panel of transmitted or early founder (T/F)
Envs. The data showed that the majority of T/F Envs used CCR5 and that many also used CCR3,
although less efficiently. Despite a similar ability to use wild-type CCR5, individual Envs differed
significantly in their sensitivity to the CCR5 inhibitors maraviroc, CMPD-167 and SCH-412147.
Inhibitor mapping experiments demonstrated that maraviroc, CMPD-167 and SCH-412147
interfered with the binding of CCR5 mAb to the C-terminal half of the second extracellular loop 2
of CCR5. Interestingly, Envs resistant to maraviroc, CMPD167 and SCH-412147 remained
sensitive to TAK-779. Further studies indicated that the sensitivity of Envs to CCR5 inhibitors
correlated with the molecular anatomy of CCR5 use, revealing that the inhibitor-sensitive Envs
barely used the CCR5 N terminus, whereas resistant Envs showed a marked increase in its use.
Taken together, these findings demonstrate that T/F R5 Envs are heterogeneous with respect to
the mechanisms of CCR5 utilization. These data may have implications for therapeutic and
prophylactic use of CCR5-based antiretrovirals.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) entry is
mediated through a complex sequence of interactions
between the gp120 subunit of the envelope glycoprotein
(Env), the cellular receptor CD4 and co-receptors C-C
chemokine receptor type 5 (CCR5) or CXCR4, which leads
to activation of gp41 and fusion of the viral envelope with
the plasma membrane. The importance of CCR5 in HIV
transmission and ongoing infection, as well as the limited
impact on health of a loss of CCR5 function seen in
homozygous D32 allele individuals, make CCR5 inhibitors
attractive candidates for both prevention and treatment.
The small-molecule CCR5 antagonist maraviroc (UK-
427857) is the first CCR5 inhibitor licensed for clinical
use (Gulick et al., 2008). Another CCR5 inhibitor,
vicriviroc (SCH-417690 or SCH-D), is currently in phase
II and phase III clinical trials (Gulick et al., 2007;
Schu ¨rmann et al., 2007).
In the absence of a protective vaccine, multi-drug
combination therapy is currently the main strategy for
HIV-1 management. However, long-term treatment of
infection has been, and continues to be, complicated by
drug resistance due to the high potential of HIV-1 for the
generation of escape mutations. HIV resistance in vitro and
in vivo to classic antiretroviral drugs (targeted at key viral
enzymes) and to the gp41 entry inhibitor enfuvirtide has
been intensively investigated. More recent studies have
addressed the mechanism of HIV-1 resistance to the CCR5
inhibitors maraviroc (Westby et al., 2007) and vicriviroc
(Anastassopoulou et al., 2009; Berro et al., 2009; Ogert
et al., 2009) using in vitro-generated drug-resistant strains.
Furthermore, the emergence of maraviroc- or vicriviroc-
resistant HIV-1 in clinical trials has also been reported
(Gulick et al., 2008; Tsibris et al., 2008). However, the
frequency of natural resistance to CCR5 inhibitors in
transmitted or early founder (T/F) viruses has not been
characterized. This may have particular importance when
considering the development of CCR5 antagonists for use
as topical microbicides to prevent sexual transmission of
HIV-1 (Klasse et al., 2008; Shattock & Moore, 2003), or for
therapy in acute infection. Therefore, it is crucial to
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CCR5 inhibitors, in particular that of T/F viruses. A
previous study reported that, compared with Envs from
chronically infected subjects, T/F Envs demonstrated
equivalent or modestly enhanced resistance to the fusion
inhibitor T1249 and broadly neutralizing antibodies (Keele
et al., 2008). In the current study, we investigated the
molecular anatomy of co-receptor (Hu et al., 2000b)
utilization by T/F Envs. In addition, we characterized the
sensitivity of T/F Envs to the small-molecule CCR5
inhibitors maraviroc, CMPD-167 and SCH-412147, and
explored the mechanisms of inhibition and natural
resistance to this class of entry inhibitors.
RESULTS
Co-receptor utilization of T/F HIV-1 Envs
A previous study by others didnotreveal a natural resistance
to a small CCR5 inhibitor in primary CCR5-using (R5)
isolates (Dorr et al., 2005). In this study, we focused
exclusively on the assessment of T/F Envs. The genetic and
phenotypic characterization of T/F HIV-1 Envs used in this
study, derived by single-genome amplification from subjects
with acute clade B viral infection, has been described
previously (Keele et al., 2008). These T/F Envs revealed a
consistent pattern of CCR5 dependence. In this study, using
a well-established Env-mediated cell–cell fusion system (Hu
et al., 2000a), we further characterized CCR3 utilization and
its association with the use of CCR5 and CXCR4. Amongst
the 20 tested T/F env clones, all used CCR5, and two clones,
WEAUd15.410.5017 and 1058_11.B11.1550, also used
CXCR4 (Fig. 1a). These two R5X4 Envs also demonstrated
good fusogenic activity with CCR3. In addition, many of the
R5 Envs were able to use CCR3, although less efficiently, and
several showed comparable use of CCR3 to the two R5X4
clones. As the V3 loop is the major determinant for co-
receptor utilization, we compared the V3 amino acid
sequences. The two R5X4 sequences had positively charged
lysine (K) or arginine (R) at position 306 (Fig. 1b), whereas
all the R5 sequences had a serine (S) or glycine (G). It is
known that the overall positive charge of the V3 loop is
correlated with the negatively charged surface of the
extracellular domains of CXCR4. Therefore, a positively
charged K or R at position 306 may account for the R5X4
phenotype. In contrast, there was no discernible motif
predicting the efficacy of CCR3 utilization.
Sensitivity of T/F HIV-1 Envs to small-molecule
CCR5 inhibitors
In addition to being used as therapeutic drugs for
treatment, CCR5 inhibitors could be used prophylactically
to prevent HIV transmission. Understanding whether T/F
Envs are sensitive to CCR5 inhibitors may provide
important information for topical microbicide develop-
ment and treatment of acute infection. We therefore
conducted experiments to test the sensitivity of T/F Envs to
the CCR5 antagonists maraviroc, CMPD-167 and SCH-
412147 in a widely used cell–cell fusion assay. Maraviroc
inhibited the fusogenic activity of the majority of R5 Envs
in a dose-dependent manner (Fig. 2a). Of interest, several
Envs, particularly 1059_09.A4.1460 and 63358.p3.4013,
Fig. 1. Co-receptor use of T/F HIV-1 Envs. (a)
Fusogenic activity of T/F HIV-1 Envs. QT6
effector cells were prepared by infection with
vTF1.1 for 1 h, followed by transfection with
Env expression constructs. Target QT6 cells
were transfected with CD4 and candidate co-
receptor in pcDNA3, and a construct encoding
luciferase under the transcriptional control of
the T7 promoter. The effector and target cell
populations were mixed at 16–18 h following
transfection, and luciferase activity of cell
lysates was determined approximately 8 h
later. Fusogenic activity was shown as relative
light units (RLU). Data are representative of
three independent experiments, with each
determination performed in triplicate (mean±
SD). (b) Alignment of V3 loop sequences of T/F
Envs. V3 loop sequences were aligned using
BioEdit 7.0. Amino acid position 306 is
indicated by an asterisk.
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infection with vTF1.1 for 1 h followed by transfection with Env expression constructs. Target QT6 cells were transfected with
CD4 and CCR5 in pcDNA3, and a construct encoding luciferase under the transcriptional control of T7 promoter. At 16–18 h
post-transfection, target cells were pre-treated with serially diluted CCR5 inhibitor maraviroc (a), CMPD-167 (b) or SCH-
412147 (c) for 30 min before mixing with effector cells. The luciferase activity of cell lysates was determined approximately 8 h
later. The fusogenic activity in medium alone was arbitrarily set to 100% for each Env. Data are representative of three
independent experiments, with each determination performed in triplicate (mean±SD).
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inhibition was not achieved even at 10 mM drug concen-
tration, whilst others were inhibited with an IC50 range
from 0.059 to 4.23 mM. Similar patterns were observed
when CMPD-167 and SCH-412147 were tested against
these same Envs (Fig. 2b, c).
To confirm the findings in fusion assays, further experi-
ments were performed in an infection assay using pseudo-
typed viruses containing the Env glycoproteins to infect
TZM-bl cells. Several Envs were tested, including the R5X4
clone WEAUd15.410.5017, the resistant clones 1059_
09.A4.1460 and 63358.p3.4013, and the highly sensitive
clone 700010040.C9.4520. Clone 1059_09.A4.1460 waspoorly
infectious in the pseudotype infection system; therefore, only
pseudotyped viruses with comparable infectivity were further
analysed. Although the three pseudotyped viruses had similar
infectivity in the absence of inhibitors, they demonstrated a
range of sensitivities to the CCR5 inhibitors (Fig. 3). Not
surprisingly, as TZM-bl cells express both CCR5 and CXCR4,
the R5X4 Env WEAUd15.410.5017 was seen to be resistant to
maraviroc, CMPD-167 and SCH-412147. In agreement with
the fusogenic results, 700010040.C9.4520 was highly sensitive
to all three CCR5 antagonists. In contrast, 63358.p3.4013 was
significantly less sensitive to the CCR5 inhibitors. Together,
these datasuggested that, whilst the majority of T/F Envs were
fully sensitive to CCR5 inhibitors, some individual T/F Envs
can differ significantly in their sensitivity to CCR5 drugs.
Mechanisms of CCR5 inhibition and inhibitor
resistance
Maraviroc, CMPD-167 and the SCH-412147-related vicri-
viroc are thought to bind to the transmembrane domains
of CCR5 (Briz et al., 2006; Kuhmann & Hartley, 2008). To
explore further the mechanisms of CCR5 inhibition, we
performed epitope mapping experiments using anti-CCR5
mAbs with specificity for the N terminus of CCR5 or for
the secondary extracellular loop (ECL2), the two primary
domains mediating HIV entry. The mAb 3A9 binds to the
N terminus of CCR5, whilst mAb 2D7 binds to the N
terminus of ECL2 and mAb 45531 to the C-terminal half of
ECL2 (Fig. 4a) (Lee et al., 1999; Wu et al., 1997). Pre-
treatment with maraviroc, CMPD-167 or SCH-412147 did
not block the binding of 3A9 and 2D7 to CCR5-expressing
Chinese hamster ovary (CHO) cells (Fig. 4a). In contrast,
maraviroc, CMPD-167 and SCH-412147 all inhibited the
binding of mAb 45531. Although these data are not a
definitive indication of physical interaction between these
CCR5 inhibitors and CCR5 ECL2, they do indicate that
their binding to the transmembrane domains of CCR5 is
sufficient to disrupt the conformation of the extracellular
domain, inhibiting binding of 45531 mAb to ELC2 and
utilization of CCR5 by sensitive R5 clones.
Our previous studies demonstrated that R5 Envs vary in
their ability to utilize the molecular anatomy of CCR5 (Hu
et al., 2000b, 2005). In the current study, we observed that
individual T/F Envs differed significantly in their sensitivity
to CCR5 inhibitors. We hypothesized that the sensitivity to
CCR5 inhibitors might be reflected by the molecular
anatomy of CCR5 use. To test this hypothesis, the fusogenic
activities of T/F Envs were examined using chimeras
between CCR5, the primary co-receptor, and CXCR2 (also
known as IL-8RB). To maintain maximal structural
integrity, the hybrid 5BBB contained the first 20 aa of
CCR5 fused to the body of CXCR2, whilst the hybrid B555
Fig. 3. Sensitivity to small-molecule CCR5 inhibitors of T/F HIV-1
Envs in pseudotyped-virus infection. Stocks of pseudotyped
reporter viruses were prepared by co-transfecting 293T cells with
Env expression constructs and plasmid pHIVDEnv for 48 h and
then harvested. TZM-bl cells were pre-treated with serially diluted
CCR5 inhibitor maraviroc (a), CMPD-167 (b) or SCH-412147 (c)
for 30 min before pseudotyped viruses were added. The luciferase
activity of cell lysates was determined approximately 24 h later.
The infectivity in medium alone was arbitrarily set to 100% for
each Env. Data are representative of three independent experi-
ments, with each determination performed in triplicate (mean±SD).
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We tested 1059_09.A4.1460 and 63358.p3.4013, together
with two sensitive env clones, 1006_11.C3.1601 and
700010040.C9.4520. All four Envs utilized B555, the body
of CCR5, although for 700010040.C9.4520 this was very
inefficient (Fig. 4b). Of note, the sensitive clones, 1006_
11.C3.1601 and 700010040.C9.4520, barely used 5BBB,
whereas 1059_09.A4.1460 and 63358.p3.4013 retained 60–
80% of their fusogenic activity with 5BBB when compared
with that of CCR5. Together, our data demonstrated that
there is a significant correlation between sensitivity to CCR5
inhibitors and the use of CCR5 chimeras by Envs.
A previous study indicated that all tested T/F R5 Envs were
sensitive to TAK-779 in a pseudotyped virus infection assay
(Keele et al., 2008). In agreement, we found that the R5 env
clones, including 1059_09.A4.1460 and 63358.p3.4013,
were sensitive to TAK-779 in a dose-dependent fashion
in the cell–cell fusion system (Fig. 4c), with an IC50 of 13.04
and 6.3 mM, respectively, despite TAK-779 being much less
potent than the other three CCR5 antagonists. As
1059_09.A4.1460 and 63358.p3.4013 showed significant
resistance to maraviroc, CMPD-167 and SCH-412147, we
looked further at the mechanism of resistance using CCR5/
CXCR2 chimeras. All four tested CCR5 inhibitors com-
pletely blocked the fusogenic activity of 1059_09.A4.1460
or 63358.p3.4013 with the body of CCR5 (B555) (Fig. 4d).
Of great interest, only TAK-779 inhibited the fusogenic
activity of 1059_09.A4.1460 or 63358.p3.4013 with the N
terminus of CCR5 in a dose-dependent manner, whilst
maraviroc, CMPD-167 and SCH-412147 did not achieve
complete inhibition even at a high concentration. TAK-779
can suppress the binding of mAb 45531 to CCR5 (Baba
et al., 1999) and the binding sites for TAK-779 on CCR5
have been suggested to be located near the extracellular
surface of the receptor, within a cavity formed between
transmembrane helices 1, 2, 3 and 7 (Dragic et al., 2000).
TAK-779 has also been reported to bind to CCR2b and
CXCR3, but there has been no evidence that it antagonizes
CXCR2 (Baba et al., 1999; Gao et al., 2003). Our data
suggested that the inhibitory mechanisms of maraviroc,
CMPD-167 and SCH-412147 may be somewhat different
to that of TAK-779.
DISCUSSION
By characterizing T/F HIV-1 Envs in cell–cell fusion and
pseudotype infection assays, as well as determining their
sensitivity to CCR5 inhibitors, we confirmed that the
majority of T/F Envs used CCR5 and identified that some
of the Envs also used CCR3, although less efficiently. In
addition, T/F Envs significantly differed in their sensitivity
to the CCR5 inhibitors maraviroc, CMPD-167 and SCH-
412147, which can interfere with the binding of anti-CCR5
mAb to the C-terminal half but not to the N terminus of
ECL2 of CCR5. Further study demonstrated that the
sensitivity of Envs to CCR5 inhibitors correlated strongly
with the molecular anatomy of CCR5 utilization.
A previous study identified and characterized T/F Envs in
primary infection from subjects including heterosexual
and homosexual encounters (Keele et al., 2008). Of the 20
full-length Envs tested in the current study, WEAUd15.
410.5017 and 1058_11.B11.1550 utilized CCR5 and CXCR4
as well as CCR3. Correspondingly, the R5X4 Envs had a
positively charged lysine or arginine at position 306.
Several R5 Envs also used CCR3, although considerably less
efficiently than CCR5. We did not observe a correlation
between transmission route and co-receptor usage.
Although we focused exclusively on the characterization
of T/F Envs in this study, previous studies have suggested
that some clade B Envs can also use CCR3 (Hu et al.,
2000a; Nedellec et al., 2009). Potential targets for CCR3-
mediated infection include microglial cells, macrophages,
eosinophils and T-helper 2 cells (Aasa-Chapman et al.,
2006). The significance of CCR3 utilization by T/F Envs
remains to be determined further. The T/F Envs dem-
onstrate equivalent or modestly enhanced resistance to the
fusion inhibitor T1249 and broadly neutralizing antibodies
(4E10, 2F5, b12 and 2G12), and less sensitivity to sCD4 and
mAb 17b (Keele et al., 2008). In the current study, we
found that they varied significantly in their sensitivity to
the CCR5 inhibitors maraviroc, CMPD-167 and SCH-
412147. Given that maraviroc, CMPD-167 and SCH-
412147 can all interfere with the binding of mAb 45531,
it is not surprising that all the tested Envs showed a similar
pattern of sensitivity to these compounds in cell–cell fusion
and pseudotype infection assays. However, at least a 3 log
higher concentration of drug was needed in the cell–cell
fusion assay to achieve a similar inhibition to that seen in
the infection assay. This discrepancy may reflect the high
cell–cell fusion efficiency mediated by HIV-1 Env, also seen
with other entry inhibitors (Reeves et al., 2002). In
addition, cell-surface expression of CCR5 may also have
influenced the potency of inhibition (Ketas et al., 2007).
Nevertheless, our findings may have biological relevance
because cell–cell spread of HIV-1 could be more efficient
than virus–cell infection.
Due to the high degree of diversity amongst the T/F Envs,
we are currently unable to identify specific sequence
variations associated with variable sensitivity to CCR5
inhibitors. Using an in vitro resistance generation system,
studies carried out by other groups have failed to reveal a
common resistance pathway against small-molecule
CCR5 inhibitors. Even under the selection pressure of
the same drug, different strains appear to escape by
mutating different Env sequences. For instance, Ogert
et al. (2008, 2009) recently reported that K305R, R315Q
and K319T amino acid changes in the V3 loop, along with
P437S in C4, completely reproduced the vicriviroc
resistance phenotype in a chimeric strain ADA envelope.
Others, however, showed that the substitutions K305R,
H308P, A316V and G321E in the V3 loop or changes of
G516V, M518V and F519I in the gp41 fusion peptide
conferred vicriviroc resistance (Anastassopoulou et al.,
2009; Berro et al., 2009). In contrast, Westby et al. (2007)
CCR5 use and inhibitor sensitivity of T/F HIV Envs
http://vir.sgmjournals.org 2969reported that two amino acid substitutions (A316T and
I323V) in the V3 loop conferred maraviroc resistance.
However, we did not observe any of these associations in
our sequences.
It is well described that the N terminus and ECL2 of CCR5
both play critical and distinct roles in HIV infection. In
particular, the tip of the V3 region of gp120 binds to ECL2
of CCR5, whilst the base and stem of V3 and the bridging
Q. Hu, X. Huang and R. J. Shattock
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previously that loss of the V3 crown b-hairpin disrupted
utilization of the body of CCR5 (Hu et al., 2000b), whilst
mutations in the stem of V3 abolished the utilization of the
N terminus and the body of CCR5 (Hu et al., 2005). In the
current study, we observed that the resistant Envs had very
high fusogenic activity with the N terminus of CCR5,
whereas the sensitive Envs barely used the CCR5 N
terminus. This is in agreement with our epitope-mapping
experiments, which demonstrated that maraviroc, CMPD-
167 and SCH-412147 interfered with the binding of mAb
45531 to the C-terminal half of ECL2. As suggested by
others, binding of the CCR5 small-molecule inhibitors
SCH-351125 (SCH-C) and SCH-350581 (AD101) to the
transmembrane domains of CCR5 may disrupt the
conformation of its extracellular domains, thereby inhib-
iting ligand binding to CCR5 (Tsamis et al., 2003). Our
findings suggest that an enhanced interaction of gp120
with the N terminus of CCR5 may account for the
resistance to small-molecule CCR5 inhibitors, which target
the body of CCR5. In agreement, using truncated CCR5
and mutants, Berro et al. (2009) and Ogert et al. (2009)
observed that in vitro-generated vicriviroc-resistant HIV-1
and Envs derived from a clade D-infected subject who
developed resistance to vicriviroc while participating in a
phase II trial (Ogert et al., 2010) had increased dependency
on interactions with the CCR5 N terminus.
Of interest, all the tested R5 Envs, including those resistant
to maraviroc, CMPD-167 and SCH-412147, were sensitive
to TAK-779. Despite these inhibitors having a similar
mechanism of action and fitting in the same binding
pocket formed by the transmembrane domains of CCR5
(Kondru et al., 2008; Maeda et al., 2006; Seibert et al.,
2006), the impact of their binding on the conformation of
CCR5 may differ between molecules. This is strengthened
by the observation that only TAK-779 was able to inhibit
the entry of Envs through the N terminus of CCR5. Our
results are in agreement with the notion that, although
small-molecule CCR5 inhibitors occupy overlapping bind-
ing pockets on the receptor and act via a similar
mechanism, the conformational details of the inhibitory
effect may differ between molecules (Kuhmann & Hartley,
2008).
Given that HIV Env is a principal target for the design of
vaccines and antiviral drugs, molecular characterization of
T/F Envs may be crucial to the design of effective
prevention strategies (McMichael et al., 2010). The findings
in this study demonstrate that T/F Envs display a wide
range of sensitivities to small-molecule CCR5 inhibitors
and this may have implications for the preventative and/or
therapeutic use of this new class of antiretrovirals.
METHODS
Cells, env genes, CCR5 inhibitors and mAbs. The Japanese quail
fibrosarcoma cell (QT6) line was purchased from the ATCC. The
TZM-bl cell line was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIH (MD, USA). The
293T cell line was purchased from Invitrogen. The CHO-CCR5 cell
line has been described previously (Hu et al., 2000a, b). The T/F env
clones have been previously described and were kindly provided by
the Centre for HIV/AIDS Vaccine Immunology (CHAVI) (Keele et al.,
2008). The CCR5 inhibitors maraviroc and SCH-412147 were
provided by the International Partnership for Microbicides. CMPD-
167 and TAK-779 have been described previously (Hu et al., 2004;
Veazey et al., 2005). PE-conjugated mouse anti-human CCR5 mAbs
3A9, 2D7 and isotype control were purchased from BD Biosciences.
PE-conjugated mouse anti-human CCR5 mAb 45531 and isotype
control were purchased from R&D Systems.
Env-mediated cell–cell fusion assay. The co-receptor utilization
of the products encoded by the env genes was determined using a cell–
cell fusion assay employing a luciferase reporter gene, as described
previously (Hu et al., 2000a). Briefly, QT6 effector cells were prepared
by infection with vTF1.1, which encodes T7 polymerase, for 1 h
followed by transfection with pcDNA3 constructs containing the
primary env clones. QT6 target cells were transfected with CD4 and
the candidate co-receptor in pcDNA3, as well as a construct encoding
luciferase under the transcriptional control of the T7 promoter. The
effector and target cell populations were mixed at 16–18 h post-
transfection. In inhibition experiments using CCR5 drugs, target cells
were pre-treated with serially diluted CCR5 inhibitors for 30 min
before mixing with effector cells. The luciferase activity of cell lysates
was determined approximately 8 h later. Constructs CD4, T7–
luciferase, CCR5, CXCR4, CXCR2 and CCR5/CXCR2 chimeras
(5BBB and B555) have been described previously (Hu et al., 2000b,
2005).
Pseudotyped virus infection. Stocks of pseudotyped reporter
viruses were prepared by co-transfecting 293T cells with Env
expression constructs and plasmid pHIVDEnv as described previously
Fig. 4. Mechanisms of CCR5 inhibition and inhibitor resistance. (a) Binding epitopes of CCR5 inhibitors. CHO-CCR5 stable
transfectants were treated with 1 mM of each respective CCR5 inhibitor for 1 h, washed extensively and stained with PE-
conjugated anti-CCR5 mAb 3A9, 2D7, 45531 or with isotype-matched control IgG before analysis by flow cytometry. hCCR5,
human CCR5; mCCR5, mouse CCR5. (b–d) Fusogenic activity of T/F HIV-1 Envs with CCR5/CXCR2 chimeras (b), with
CCR5 in the presence of CCR5 inhibitor TAK-779 (c) and with CCR5/CXCR2 chimeras in the presence of the CCR5 inhibitor
maraviroc, CMPD-167, SCH-412147 or TAK-779 (d). QT6 effector cells were prepared by infection with vTF1.1 for 1 h,
followed by transfection with Env expression constructs. Target QT6 cells were transfected with CD4 and CCR5 or CCR5/
CXCR2 chimera in pcDNA3, and a construct encoding luciferase under the transcriptional control of the T7 promoter. The
effector and target cell populations were mixed at 16–18 h after transfection, and the luciferase activity of cell lysates was
determined approximately 8 h later. In experiments using CCR5 drugs, target cells were pre-treated with serially diluted CCR5
inhibitor for 30 min before mixing. The fusogenic activity with CCR5 was arbitrarily set to 100%. Data are representative of
three independent experiments, with each determination performed in triplicate (mean±SD).
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pre-treated with serially diluted CCR5 inhibitors for 30 min. The
luciferase activity of cell lysates was determined at 48 h post-
transfection.
Flow cytometry. CHO-hCCR5 cells were treated with 1 mM of the
respective CCR5 inhibitor at 37 uC for 1 h and then stained with anti-
CCR5 mAb. Cells were analysed on a FACScan device (Becton
Dickinson) as described previously (Hu et al., 2004).
Sequence analysis. The sequences of HIV-1 env genes have been
reported previously (Keele et al., 2008). The amino acid sequences of
env genes were aligned using BioEdit 7.0.
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